Mutation of PIK3CA, usually an indicator of induced PI3K/AKT/mTOR signaling and a marker predictive of response to the PI3K inhibitors in hormone receptor (HR)-positive BC patients15,16, was found to occur less frequently in obese patients with NST ER+/HER2−. This evidence concerns the gene NR4A1 and breast cancer.